CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Mukul Agrawal and Vijay Kedia Gains Rs 6.71 Crore and Rs 19.19 Crore as Stock Hits Upper Circuit Today: Stock Rallies Over 900 Per cent in Just 2 Years!
Rakesh Deshmukh

Mukul Agrawal and Vijay Kedia Gains Rs 6.71 Crore and Rs 19.19 Crore as Stock Hits Upper Circuit Today: Stock Rallies Over 900 Per cent in Just 2 Years!

The company’s shares have delivered a multibagger return of over 200 per cent in the past 1 year.

Neuland Laboratories Ltd is an India-based company engaged in the manufacturing and selling of bulk drugs, serving both domestic and international markets. The company is an active pharmaceutical ingredient (API) manufacturing and development organization that caters to the chemistry needs of the pharmaceutical and biotech industries. It provides solutions across the full range of the pharmaceutical industry’s chemistry requirements, from synthesizing library compounds to supplying New Chemical Entities (NCEs) and advanced intermediates at various stages of the clinical life cycle, as well as during commercial launch.

At the start of the day's trading session, shares of Neuland Laboratories Ltd opened at Rs 11249.15 per share, compared to the previous day's closing figure of Rs 11668.90 per share on the BSE. Finally, the shares closed at Rs 11644.10 per share. The stock has rallied 5 per cent today and hit the upper circuit, reflecting strong demand in the market. The company's current market capitalization stands at Rs 14939 crore, and the stock has generated an impressive multibagger return of over 200 per cent in the past 1 year.

Ace investors Vijay Kedia and Mukul Agrawal have seen significant gains as the stock hit the upper circuit today. Vijay Kedia, who owns 1,40,000 shares, has realized gains of Rs 6,71,72,000, while Mukul Agrawal, with 400,000 shares, has accrued gains of Rs 19,19,20,000. The share price surged by Rs 479.8 today, contributing to these substantial gains.

DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.

As per the Quarterly Results, in Q4 FY24, Neuland Laboratories Ltd recorded a revenue of Rs 440 crore representing a growth of 21 per cent YoY from Rs 363 crore. The operating profit for Q4 FY24 stood at Rs 123 crore. The net profit for Q4 FY24 was Rs 98 crore compared to a profit of Rs 62 crore. Looking at the annual performance, the company generated a revenue of Rs 1559 crore in FY24, compared to Rs 1191 crore in FY23. The operating profit for FY24 was Rs 463 crore with a net profit of Rs 300 crore.

According to the shareholding pattern of Neuland Laboratories Ltd, promoters own a 32.72 per cent stake, while public investors hold 34.77 per cent. FIIs hold a 25.72 per cent stake and DIIs own a 6.39 per cent in Q1 FY25. Mukul Agrawal and Vijay Kedia owns a 3.12 per cent and 1.09 per cent stake in the company.

Investors must keep this Small-Cap stock on their radar. 

Disclaimer: The article is for informational purposes only and not investment advice.
 

Previous Article Market wrap: The benchmark indices concluded the trading day on a negative note!
Next Article Rooting For The Straddle Strategy
Print
604 Rate this article:
5.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR